Dasatinib dosage and administration

Dasatinib (Dasatinib) is a tyrosine kinase inhibitor used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) or chronic myelogenous leukemia (CML). It is an oral tablet. The specific dosage and usage are as follows. If patients use dasatinib, they must also refer to its instructions.

1. Recommended dosage: (1) Adult patients: The recommended starting dose for chronic phase CML is 100 mg orally once a day; for accelerated phase CML, myeloid or lymphoblastic phase CML or Ph+ ALL, the recommended starting dose is 140 mg orally once a day. Dasatinib can be taken in the morning or evening with or without food.

(2) Pediatric patients: The recommended starting dose is based on body weight and the recommended dose should be taken orally once daily with or without food. The dose for patients weighing ≥10 to <20 kg is 40 mg; for patients weighing ≥20 to <30 kg, the dose is 60 mg; for patients weighing ≥30 to <45 kg, the dose is 70 mg; and for patients weighing at least ≥45 kg, the dose is 100 mg. Based on changes in body weight, the dose is recalculated every 3 months or more frequently if necessary.

For pediatric patients withPh+ ALL, initiate dasatinib treatment on or before day 15 of induction chemotherapy, when diagnosis is confirmed, and continue for 2 years. Tablets are not recommended for patients weighing <10kg.

2. Dose escalation: For adult patients with CML and Ph+ ALL who do not achieve a hematological or cytogenetic response at the recommended starting dose, a dose increase to 140 mg/day (chronic phase CML) or 180 mg/day (advanced CML and Ph+ ALL) may be considered. For pediatric patients with chronic myelogenous leukemia, consider increasing the dose to 120 mg once daily. Dose escalation is not recommended in pediatric patients with Ph+ ALL, in which case dasatinib is given concomitantly with chemotherapy.

3. Duration of treatment: In clinical studies, adult and pediatric patients with chronic phase CML continue to be treated with dasatinib until the disease progresses or the patient no longer tolerates it. The impact of discontinuing treatment after achieving cytogenetic response (including complete cytogenetic response [CCyR]) or major molecular response (MMR and MR4.5) on long-term disease outcomes has not been determined. In clinical studies, the maximum duration of treatment with dasatinib in pediatric patients with Ph+ ALL was 2 years.

The original drug of dasatinib has been launched in China and is included in medical insurance. Currently, reimbursement is only available to eligible patients. Common specificationsThe price of each box of 50mg*60 tablets may be around RMB 10,000, and overseas original drugs are even more expensive. Dasatinib generics are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of a box of 50mg*60 tablets produced by an Indian pharmaceutical factory may be several hundred yuan (the price may fluctuate due to exchange rates).